眼底激光联合雷珠单抗用于糖尿病视网膜病变治疗中的价值

The value of fundus laser combined with renizumab in the treatment of diabetic retinopathy

目的:探究眼底激光联合雷珠单抗用于糖尿病视网膜病变治疗中的价值。方法:择取于2016-10~2018-10就本院312例行糖尿病视网膜病变治疗的患者为对象。基于随机分组法将其均分为两组,对照组与观察组各156例。对照组采用单一眼底激光治疗方案,观察组采用眼底激光联合雷珠单抗治疗,对比分析两组患者的视力改善及眼底评估情况。结果:观察组患者的视力改善情况(改善率:96.79%)明显优于对照组(改善率:86.54%),差异对比具有统计学意义(P<0.05);观察组患者的眼底评估状况(眼底出血时间:2.33±0.11、渗出吸收时间:10.53±0.79、视网膜水肿改善时间:4.65±0.12)明显优于对照组的眼底评估状况(眼底出血时间:3.10±0.44、渗出吸收时间:11.91±1.21、视网膜水肿改善时间:5.63±0.46)。结论:就糖尿病视网膜病变运用眼底激光及雷珠单抗联合治疗临床效果理想,该方式具有显著改善患者视力及视网膜相关症状的效果,同时缩短眼底出血时间和视网膜水肿改善时间,安全性和有效性更高,值得进一步推广和应用。

Objective: To explore the value of fundus laser combined with renizumab in the treatment of diabetic retinopathy.Methods: Three hundred and twelve patients with diabetic retinopathy treated in our hospital from October 2016 to October 2018 were selected for the study, and were randomly divided into control group and observation group with 156 cases each.The control group was treated with single fundus laser, while the observation group was treated with fundus laser combined with leizumab.Results: The visual acuity improvement rate of the observation group(96.79%) was significantly better than that of the control group(86.54%), and the difference was statistically significant(P<0.05).The fundus assessment status of the observation group was significantly better than that of the control group, such as fundus hemorrhage time(2.33±0.11 vs. 3.10±0.44)d, exudate absorption time(10.53±0.79 vs. 11.91±1.21)d, and retinal edema improvement time(4.65±0.12 vs. 5.63±0.46).Conclusion: Fundus laser combined with leizumab has an ideal clinical effect in the treatment of diabetic retinopathy, which can significantly improve the visual acuity and retina-related symptoms, shorten the time of fundus hemorrhage and improve the time of retinal edema, with higher safety and effectiveness.